Cadrenal (CVKD) insider sales total $106K; Form 144 filed

Rhea-AI Filing Summary

Form 144 filed for Cadrenal Therapeutics, Inc. (CVKD) reporting proposed and recent insider sales. The notice shows a proposed sale of 6,790 common shares through Merrill Lynch (Ponte Vedra Beach, FL) with an aggregate market value of $95,661.94 and an approximate sale date of 09/24/2025 on NASDAQ. The shares were acquired as Founders Shares on 01/25/2022 from the issuer. The filing also discloses sales by Quang X. Pham during the past three months: 3,836 shares on 08/27/2025 (gross proceeds $53,455.56), 1,193 shares on 08/28/2025 (gross proceeds $16,540.64), and 2,581 shares on 09/24/2025 (gross proceeds $36,108), totaling $106,104.20 in gross proceeds.

Positive

• None.

Negative

• Insider sales disclosed: Recent sales by Quang X. Pham generated $106,104.20 in gross proceeds over August–September 2025.
• Proposed additional sale: A Form 144 lists a proposed sale of 6,790 common shares valued at $95,661.94 with an approximate sale date of 09/24/2025.

Insights

Securities Analyst

TL;DR: Insider founder sold multiple blocks totaling $106,104.20 in recent months; a Form 144 notifies proposed additional sales.

The Form 144 discloses a proposed 6,790-share sale valued at $95,661.94 scheduled for 09/24/2025 and identifies prior sales by Quang X. Pham in August and September 2025 that generated $106,104.20 in gross proceeds. The shares to be sold were acquired as founders shares on 01/25/2022 from the issuer. From a trading-impact perspective, these are explicit, reported insider-disposition events; the filing provides transaction dates, quantities, broker, and values but does not state intent or provide context such as percentage ownership change or lock-up expiration.

Corporate Governance Expert

TL;DR: The filing documents compliant disclosure of insider sales and a representation that no material undisclosed information is known.

The Form 144 includes the standard certification that the seller does not possess undisclosed material adverse information and lists the broker (Merrill Lynch) and exchange (NASDAQ). It confirms the securities were originally issued as founders shares on 01/25/2022. The document is procedural and provides required transaction transparency; it does not contain governance actions, plan adoption dates, or 10b5-1 plan information in the remarks section.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 824 A1A North Suite 200 Ponte Vedra Beach FL 32082	6790	95661.94	2046854	09/24/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/25/2022	Founders Shares	Issuer			6790	01/25/2022	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Quang X. Pham 830 A1A North Suite 196 Ponte Vedra Beach FL 32082	Common	08/27/2025	3836	53455.56
Quang X. Pham 830 A1A North Suite 196 Ponte Vedra Beach FL 32082	Common	08/28/2025	1193	16540.64
Quang X. Pham 830 A1A North Suite 196 Ponte Vedra Beach FL 32082	Common	09/24/2025	2581	36108

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 for Cadrenal Therapeutics (CVKD) report?

The filing reports a proposed sale of 6,790 common shares (aggregate value $95,661.94) and prior insider sales totaling $106,104.20.

Who conducted the brokered sale listed on the Form 144?

The broker named in the filing is Merrill Lynch with an address in Ponte Vedra Beach, FL; the exchange listed is NASDAQ.

When were the shares being sold originally acquired?

The securities to be sold were acquired as Founders Shares on 01/25/2022 from the issuer.

What were the dates and proceeds of the insider sales in the past three months?

Sales occurred on 08/27/2025 (3,836 shares, $53,455.56), 08/28/2025 (1,193 shares, $16,540.64), and 09/24/2025 (2,581 shares, $36,108).

Does the filing state any 10b5-1 plan adoption date or similar instruction?

No plan adoption date or 10b5-1 instruction date is provided in the remarks section of the filing.